



## **Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences**

November 10, 2022

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate at two upcoming investor conferences:

### **J.P. Morgan Equity Opportunities Forum**

Monday, November 14 – Tuesday, November 15, 2022 in Miami, FL

### **Evercore ISI 5th Annual HealthCONx Virtual Conference**

Tuesday, November 29, 2022 at 12:35 pm ET.

A live and archived webcast of the Company's fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual Conference can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at [www.intracellulartherapies.com](http://www.intracellulartherapies.com). Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

### **About Intra-Cellular Therapies**

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit [www.intracellulartherapies.com](http://www.intracellulartherapies.com).

### **Contact:**

Intra-Cellular Therapies, Inc.  
Juan Sanchez, M.D.  
Vice President, Corporate Communications and Investor Relations  
646-440-9333

Burns McClellan, Inc.  
Lisa Burns  
[cradinovic@burnsmc.com](mailto:cradinovic@burnsmc.com)  
212-213-0006



Source: Intra-Cellular Therapies Inc.